OMERS ADMINISTRATION Corp Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

OMERS ADMINISTRATION Corp increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 20.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,296 shares of the medical equipment provider's stock after purchasing an additional 10,431 shares during the period. OMERS ADMINISTRATION Corp's holdings in Boston Scientific were worth $5,475,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. TFC Financial Management Inc. grew its position in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $29,000. Valley National Advisers Inc. raised its stake in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares during the period. Finally, Fairway Wealth LLC purchased a new stake in Boston Scientific during the 4th quarter worth $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on BSX shares. Truist Financial lifted their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Stifel Nicolaus boosted their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. Royal Bank of Canada increased their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Finally, Robert W. Baird increased their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $114.74.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the sale, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at $157,379,150.88. This trade represents a 9.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 265,820 shares of company stock valued at $27,406,958. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

BSX stock traded up $0.39 during mid-day trading on Monday, hitting $106.43. The company had a trading volume of 1,795,736 shares, compared to its average volume of 7,629,600. The stock's fifty day moving average price is $99.18 and its two-hundred day moving average price is $96.74. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market cap of $157.45 billion, a PE ratio of 85.12, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the firm earned $0.56 EPS. The business's revenue for the quarter was up 20.9% compared to the same quarter last year. On average, analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.